ResMed Inc.

NYSE:RMD

Medical - Devices

Healthcare
$242.61 +0.85%

+$1.58 today

Market cap
$34.12B
Beta
0.78
P/E (TTM)
18.1
EPS (TTM)
$10.37
Dividend yield
1.28%
52W Low $180.27High $293.81

Volume 1.22M

Average 1.32M

RMD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

ResMed Inc.NYSE: RMD

Research & Development · Q4 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q4 FY2026 research & development of $105.73M rose 22.3% year over year, ahead of the +14.2% change in trailing-twelve-month research & development. Sequentially, it rose 12.2% from the prior quarter. Over 3 fiscal years it compounded at +9.6% a year.

Context

  • Research & development amounted to 6.7% of revenue in FY2026, up 0.3 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.3% holds above the trailing-twelve-month pace of +14.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$105.73M+12.2% QoQ
Last fiscal yearJun 2026
$378.29M+14.2% YoY
LTMJun 2026
$378.28M+14.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.3%——
1 year+14.2%——
3-year CAGR+9.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
378.29M USD
Year-over-year change
+14.2%
4-year CAGR
+10.5%

Research & Development vs competitors

How RMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.2% is the 5th highest of 9, against a peer median of +11.1%.
  • Research & development amounts to 6.7% of revenue for RMD, versus a peer median of 8.8%.
RMD Competitors
Research & Development for RMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$2.92B USD+4.9%+2.1%7.8%
BSXBoston Scientific CorporationLTM Jun 2026$2.15B USD+17.3%+15.8%10.3%
PHGKoninklijke Philips N.V.LTM Jun 2026€1.72B EUR-2.6%-6.7%9.7%
ISRGIntuitive Surgical, Inc.LTM Sep 2026$1.49B USD+19.2%+14.3%12.9%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$1.32B USD+1.2%+7.1%6.5%
RMDResMed Inc.LTM Jun 2026$378.28M USD+14.2%+9.6%6.7%
TFXTeleflex IncorporatedLTM Jun 2026$195.47M USD+23.6%-2.0%7.5%
INSPInspire Medical Systems, Inc.LTM Jun 2026$99.68M USD-9.7%+14.5%11.1%
ELMDElectromed, Inc.LTM Mar 2026$1.29M USD+48.0%-9.8%1.8%
Peer median (excluding RMD) —+11.1%+4.6%8.8%

Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue3.58B4.22B4.69B5.15B5.65B
Cost of Revenue1.55B1.87B2.03B2.09B2.2B
Gross Profit2.02B2.36B2.66B3.05B3.45B
Gross Margin56.6%55.8%56.7%59.4%61.1%
Research & Development253.58M287.64M307.53M331.28M378.29M
Selling, General & Admin739.37M874M917.14M991.02M1.12B
Operating Expenses1.02B1.22B1.34B1.37B1.54B
Depreciation & Amortization193.84M197.56M216.21M235.81M244.15M
EBITDA1.18B1.36B1.53B1.91B2.15B
EBITDA Margin32.9%32.2%32.7%37.2%38.1%
Operating Income1B1.13B1.32B1.69B1.91B
Operating Margin28.0%26.8%28.2%32.7%33.8%
Interest Income00000
Interest Expense22.31M47.38M45.71M12.61M0
Other Income / Expenses(39.8M)(30.21M)(55.1M)(7.8M)10.96M
Income Before Tax960.48M1.1B1.26B1.68B1.92B
Pre-Tax Margin26.8%26.1%27.0%32.6%34.0%
Income Tax Expense181.05M204.11M243.85M276.84M396.12M
Net Income779.44M897.56M1.02B1.4B1.52B
Net Margin21.8%21.3%21.8%27.2%26.9%
EPS (Basic)5.346.126.949.5510.44
EPS (Diluted)5.306.096.929.5110.40
Weighted Avg Shares146.07M146.77M147.02M146.72M144.71M
Weighted Avg Shares (Diluted)147.04M147.46M147.55M147.34M144.98M

ResMed Inc.

NYSE:RMD

Intrinsic Alpha fair value

Locked

Current Price

$242.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.